MCID: CHL006
MIFTS: 31

Childhood Oligodendroglioma

Categories: Cancer diseases

Aliases & Classifications for Childhood Oligodendroglioma

MalaCards integrated aliases for Childhood Oligodendroglioma:

Name: Childhood Oligodendroglioma 12 15
Oligodendroglioma, Childhood 72
Pediatric Oligodendroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3183
MeSH 44 D009837
NCIt 50 C4045
UMLS 72 C0280475

Summaries for Childhood Oligodendroglioma

MalaCards based summary : Childhood Oligodendroglioma, also known as oligodendroglioma, childhood, is related to oligodendroglioma and adult oligodendroglioma, and has symptoms including seizures and headache. An important gene associated with Childhood Oligodendroglioma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1), and among its related pathways/superpathways are Citrate cycle (TCA cycle) and Peroxisome. The drugs Cyclophosphamide and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and bone, and related phenotypes are Downregulation of NF-kappaB pathway after LMP1 stimulation and Downregulation of NF-kappaB pathway after TNFalpha stimulation

Related Diseases for Childhood Oligodendroglioma

Diseases related to Childhood Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 oligodendroglioma 30.1 IDH2 IDH1
2 adult oligodendroglioma 30.0 IDH2 IDH1
3 pilocytic astrocytoma 10.2 KIAA1549 IDH1
4 nervous system cancer 10.2 IDH2 IDH1
5 interval angle-closure glaucoma 10.2 IDH2 IDH1
6 enchondroma 10.2 IDH2 IDH1
7 intracranial chondrosarcoma 10.2 IDH2 IDH1
8 chondrosarcoma 10.2 IDH2 IDH1
9 cerebellar astrocytoma 10.1 KIAA1549 IDH1
10 cytogenetically normal acute myeloid leukemia 10.1 IDH2 IDH1
11 chondroblastic osteosarcoma 10.1 IDH2 IDH1
12 intraductal papilloma 10.1 IDH2 IDH1
13 multiple enchondromatosis, maffucci type 10.1 IDH2 IDH1
14 spindle cell hemangioma 10.1 IDH2 IDH1
15 periosteal chondrosarcoma 10.1 IDH2 IDH1
16 glioma susceptibility 1 10.1 IDH2 IDH1
17 adult astrocytic tumour 10.1 IDH2 IDH1
18 diffuse infiltrative lymphocytosis syndrome 10.1 IDH2 IDH1
19 undifferentiated pleomorphic sarcoma 10.1 IDH2 IDH1
20 drug psychosis 10.1 IDH2 IDH1
21 drug-induced mental disorder 10.0 IDH2 IDH1
22 2-hydroxyglutaric aciduria 10.0 IDH2 IDH1
23 anaplastic oligodendroglioma 10.0
24 d-2-hydroxyglutaric aciduria 1 10.0 IDH2 IDH1
25 bile duct adenocarcinoma 10.0 IDH2 IDH1
26 enchondromatosis, multiple, ollier type 10.0 IDH2 IDH1
27 brain stem glioma 9.9 IDH2 IDH1
28 visual epilepsy 9.9
29 seizure disorder 9.9
30 intrahepatic cholangiocarcinoma 9.9 IDH2 IDH1
31 astrocytoma 9.9
32 cranial nerve palsy 9.9
33 mixed oligodendroglioma-astrocytoma 9.9
34 oligoastrocytoma 9.9
35 rare tumor 9.9
36 essential thrombocythemia 9.8 IDH2 IDH1
37 myelofibrosis 9.7 IDH2 IDH1
38 pilocytic astrocytoma of cerebellum 9.7 KIAA1549 IDH2 IDH1
39 fibrillary astrocytoma 9.7 KIAA1549 IDH2 IDH1
40 cerebrum cancer 9.7 KIAA1549 IDH2 IDH1
41 supratentorial cancer 9.7 KIAA1549 IDH2 IDH1
42 central nervous system cancer 9.7 KIAA1549 IDH2 IDH1
43 myeloma, multiple 9.5 IDH2 IDH1

Graphical network of the top 20 diseases related to Childhood Oligodendroglioma:



Diseases related to Childhood Oligodendroglioma

Symptoms & Phenotypes for Childhood Oligodendroglioma

UMLS symptoms related to Childhood Oligodendroglioma:


seizures, headache

GenomeRNAi Phenotypes related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Downregulation of NF-kappaB pathway after LMP1 stimulation GR00199-A-1 8.96 PDCD5 PLPP3
2 Downregulation of NF-kappaB pathway after TNFalpha stimulation GR00199-A-2 8.62 PDCD5 PLPP3

Drugs & Therapeutics for Childhood Oligodendroglioma

Drugs for Childhood Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
3
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
4
leucovorin Approved Phase 3 58-05-9 143 6006
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
7
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
8
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12 Antirheumatic Agents Phase 3
13 Immunosuppressive Agents Phase 3
14 Folic Acid Antagonists Phase 3
15 Nucleic Acid Synthesis Inhibitors Phase 3
16 Antimetabolites Phase 3
17 Antimetabolites, Antineoplastic Phase 3
18 Peripheral Nervous System Agents Phase 3
19 BB 1101 Phase 3
20 Antiemetics Phase 3
21 Autonomic Agents Phase 3
22 Emetics Phase 3
23 Gastrointestinal Agents Phase 3
24 Neurotransmitter Agents Phase 3
25 Anti-Allergic Agents Phase 3
26 Serotonin Antagonists Phase 3
27 Histamine H1 Antagonists Phase 3
28 Histamine Antagonists Phase 3
29 Dermatologic Agents Phase 3
30 Serotonin Agents Phase 3
31
Histamine Phosphate Phase 3 51-74-1 65513
32 Antipruritics Phase 3
33
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
36
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
37
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
38
Tamoxifen Approved Phase 2 10540-29-1 2733526
39
Sodium citrate Approved, Investigational Phase 2 68-04-2
40
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
41
Acetaminophen Approved Phase 2 103-90-2 1983
42
Promethazine Approved, Investigational Phase 2 60-87-7 4927
43
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
44
Iodine Approved, Investigational Phase 2 7553-56-2 807
45
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
46
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
47
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
48
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
50 Immunologic Factors Phase 2

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
3 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
4 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
6 Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
7 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
8 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
9 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
10 A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma Completed NCT00124657 Phase 1, Phase 2 Erlotinib hydrochloride
11 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
12 PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS Completed NCT00002749 Phase 2 carboplatin
13 A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas Completed NCT00238264 Phase 2
14 Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide Completed NCT00004068 Phase 2 irinotecan hydrochloride;temozolomide
15 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
16 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
17 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
18 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
19 A Phase I/II Study Of A Recombinant Chimeric Protein Composed Of Transforming Growth Factor (TGF)-a And A Mutated Pseudomonas Exotoxin Termed PE38 (TP-38) In Pediatric Patients With Recurrent Or Progressive Supratentorial High Grade Gliomas Terminated NCT00074334 Phase 1, Phase 2
20 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
21 Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
22 Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors Completed NCT01158300 Phase 1 VEGF inhibitor PTC299
23 Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis Completed NCT00006246 Phase 1 busulfan
24 A Trial of 06-BG and BCNU in Children With CNS Tumors Completed NCT00003765 Phase 1 O6-benzylguanine;carmustine
25 Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
26 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
27 A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
28 A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
29 Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias Completed NCT00030108 Phase 1 ixabepilone
30 TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY Completed NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
31 A Phase I Study of Vinblastine in Combination With Carboplatin for Children With Newly Diagnosed and Recurrent Low-Grade Gliomas Completed NCT00352495 Phase 1 carboplatin;vinblastine sulfate
32 Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients Completed NCT00107185 Phase 1
33 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
34 A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
35 A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas Completed NCT01273090 Phase 1 imetelstat sodium
36 A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Peripheral Blood Cells With O6-Methylguanine DNA Methyltransferase Completed NCT00005796 Phase 1 lomustine;procarbazine hydrochloride;vincristine sulfate
37 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
38 A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors Terminated NCT00006247 Phase 1 semaxanib
39 Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors Terminated NCT00238173 Phase 1 acetylcysteine;carboplatin;cyclophosphamide;etoposide phosphate;mannitol;sodium thiosulfate
40 A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies Terminated NCT00572182 Phase 1 MK-0752
41 A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis Terminated NCT00112619 Phase 1 topotecan hydrochloride
42 Efficacy of Gelclair™ in Reducing the Pain of Oral Mucositis in Children and Young People With Cancer (SC 2005 07) Unknown status NCT00349024 polyvinylpyrrolidone-sodium hyaluronate gel
43 Translation Study for Children and Adolescents With Low Grade Glioma Unknown status NCT00891722
44 A Pilot Study Using Carboplatin, Vincristine And Temozolomide For Children ≤ 10 Years With Progressive/Symptomatic Low-Grade Gliomas Completed NCT00077207 carboplatin;temozolomide;vincristine sulfate
45 Metabolic Syndrome in Childhood Cancer Survivors Completed NCT00920738
46 Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment Completed NCT00002485
47 Diagnostic and Prognostic Markers in Low-Grade Gliomas Completed NCT01004523
48 A Pharmacokinetic Participation Questionnaire Study Completed NCT00890435
49 Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma Completed NCT00276640 vincristine, carboplatin;vincristine, carboplatin, etoposide

Search NIH Clinical Center for Childhood Oligodendroglioma

Genetic Tests for Childhood Oligodendroglioma

Anatomical Context for Childhood Oligodendroglioma

MalaCards organs/tissues related to Childhood Oligodendroglioma:

41
Brain, Liver, Bone

Publications for Childhood Oligodendroglioma

Articles related to Childhood Oligodendroglioma:

# Title Authors PMID Year
1
Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation. 38
29192869 2018
2
Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. 38
29131101 2018
3
Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. 38
26206478 2016
4
Conventional and advanced (DTI/SWI) neuroimaging findings in pediatric oligodendroglioma. 38
25813856 2015
5
Well-differentiated pediatric glial neoplasms with features of oligodendroglioma, angiocentric glioma and dysembryoplastic neuroepithelial tumors: a morphological diagnostic challenge. 38
24448703 2014
6
Homozygous deletion of TNFRSF4, TP73, PPAP2B and DPYD at 1p and PDCD5 at 19q identified by multiplex ligation-dependent probe amplification (MLPA) analysis in pediatric anaplastic glioma with questionable oligodendroglial component. 38
24387276 2014
7
Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. 38
22941225 2012
8
Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. 38
19934553 2009

Variations for Childhood Oligodendroglioma

Expression for Childhood Oligodendroglioma

Search GEO for disease gene expression data for Childhood Oligodendroglioma.

Pathways for Childhood Oligodendroglioma

Pathways related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.17 IDH2 IDH1
2 10.87 IDH2 IDH1
3
Show member pathways
9.74 IDH2 IDH1

GO Terms for Childhood Oligodendroglioma

Cellular components related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxisome GO:0005777 8.62 IDH2 IDH1

Biological processes related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tricarboxylic acid cycle GO:0006099 9.32 IDH2 IDH1
2 2-oxoglutarate metabolic process GO:0006103 9.26 IDH2 IDH1
3 NADP metabolic process GO:0006739 9.16 IDH2 IDH1
4 isocitrate metabolic process GO:0006102 8.96 IDH2 IDH1
5 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Childhood Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NAD binding GO:0051287 9.26 IDH2 IDH1
2 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.16 IDH2 IDH1
3 isocitrate dehydrogenase activity GO:0004448 8.96 IDH2 IDH1
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH2 IDH1

Sources for Childhood Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....